Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Theraflu clears stuffiness faster for acute cold and flu symptoms, typically within 30 minutes to an hour, because it’s designed specifically for immediate relief of nasal congestion. Tezspire, by contrast, is a prescription biologic injection for asthma management that works over weeks to reduce chronic inflammation—it’s not intended for rapid relief of congestion from colds or flu. If you’re dealing with sudden stuffiness from a cold, Theraflu delivers measurable relief within your first dose.
If you have chronic asthma or persistent respiratory issues, Tezspire may improve overall congestion over time by reducing baseline airway inflammation, but it won’t help with acute cold symptoms. For someone managing dementia or cognitive health concerns, understanding these differences matters because respiratory function directly affects brain oxygenation and overall wellbeing. An older adult with a cold who needs immediate relief needs Theraflu. Someone with chronic asthma who also has cognitive decline may benefit from discussing Tezspire with their doctor because reducing medication burden and improving breathing can simplify their overall care routine.
Table of Contents
- How Do Tezspire and Theraflu Work Differently for Congestion Relief?
- Understanding the Limitations and Risks of Each Approach
- Congestion in Older Adults and Those with Cognitive Decline
- Practical Comparison for Real-World Use
- Drug Interactions and Safety Concerns in Dementia Care
- When Congestion Persists Despite Treatment
- The Future of Congestion Management and Respiratory Health in Aging
- Conclusion
How Do Tezspire and Theraflu Work Differently for Congestion Relief?
Theraflu is an over-the-counter combination medication containing acetaminophen, dextromethorphan (cough suppressant), and phenylephrine (decongestant). The phenylephrine works by constricting blood vessels in the nasal passages, reducing swelling and opening airways within 30-45 minutes of taking the product. It’s designed for acute symptoms—cold, flu, or sinus congestion that comes on suddenly. A person who wakes up unable to breathe through their nose can take Theraflu and expect genuine relief by mid-morning. Tezspire (tezepelumab) works through an entirely different mechanism. It’s a monoclonal antibody injection given once every four weeks that blocks thymic stromal lymphopoietin (TSLP), a protein involved in airway inflammation.
Rather than opening passages acutely, it reduces the underlying inflammation that causes airways to swell in the first place. Someone starting Tezspire for asthma might notice congestion improving gradually over two to four weeks as the inflammation subsides, but they won’t experience the immediate clearing that Theraflu provides. The timing difference is critical. Theraflu is for “right now” relief; Tezspire is for “better overall” control. For dementia patients who may become distressed by sudden breathing difficulty, Theraflu offers immediate comfort. For those with chronic asthma, Tezspire reduces the frequency of breathing problems altogether—but only with consistent use over time.
Understanding the Limitations and Risks of Each Approach
Theraflu has real limitations for chronic congestion or frequent users. Phenylephrine’s decongestant effect weakens with repeated use—a phenomenon called tachyphylaxis. Someone using Theraflu multiple times daily for more than three to five days may find it increasingly ineffective, which is why many decongestants carry warnings against use beyond one week. Additionally, phenylephrine can raise blood pressure and heart rate, making it risky for older adults with hypertension or cardiac conditions, which is particularly relevant in dementia populations where cardiovascular comorbidities are common. Tezspire carries different risks that require careful monitoring. As an immunosuppressant therapy, it increases susceptibility to infections and requires baseline blood work and ongoing monitoring.
Someone with dementia whose immune status and medication adherence are already challenging may struggle with the four-week injection schedule or might miss important follow-up appointments. There’s also a small risk of parasitic infections with TSLP inhibitors, so anyone with parasitic infection history needs discussion with their doctor before starting. Neither medication is safe for unsupervised use in dementia patients. Theraflu’s sedating antihistamines can worsen confusion or drowsiness in someone with cognitive decline. Tezspire requires medical supervision and isn’t something a patient or family member can decide on independently. The “limitation” here is that the faster option (Theraflu) shouldn’t be used long-term, and the longer-term option (Tezspire) requires specialist involvement and monitoring.
Congestion in Older Adults and Those with Cognitive Decline
Stuffiness in older adults isn’t just an annoying symptom—it directly affects oxygen delivery to the brain. Research shows that chronic airway obstruction correlates with cognitive decline, and even acute congestion can worsen delirium or confusion in someone with dementia. An 82-year-old with moderate dementia who gets a cold and becomes severely congested isn’t just uncomfortable; they’re at risk of acute confusion, falls, and potentially pneumonia if they can’t clear respiratory secretions. For this population, Theraflu offers a genuine safety benefit when used appropriately.
Immediate decongestion prevents the cascade of complications from hypoxia and respiratory distress. However, the phenylephrine in Theraflu can increase confusion in some older adults through blood pressure or heart rate changes, creating a paradox: it opens the airway but potentially worsens cognitive function. Tezspire’s chronic approach is valuable here too, but for a different reason. An older adult with asthma and dementia who gets multiple respiratory infections annually—each one worsening their cognitive state temporarily—might benefit from Tezspire’s reduction in baseline inflammation, leading to fewer infections overall. The prevention strategy reduces crisis events rather than treating them acutely.
Practical Comparison for Real-World Use
Consider a scenario: a 75-year-old with mild cognitive impairment wakes up with a bad cold and can’t breathe. Theraflu is the practical choice. It’s available at any pharmacy, doesn’t require a prescription or doctor visit, and starts working within the hour. A caregiver can administer it, monitor for side effects, and move on with the day. For acute, episodic congestion—which is most people’s experience with colds and flu—Theraflu is the faster, simpler solution. Now consider a different scenario: a 70-year-old with dementia and poorly controlled asthma who has three to four respiratory exacerbations annually, each one requiring antibiotics and causing temporary cognitive decline.
Tezspire requires enrollment in a treatment program, potentially a specialist visit, baseline blood tests, and ongoing monitoring. But if it reduces exacerbations to one per year, it might prevent hospitalizations, reduce medication complexity, and stabilize cognitive function overall. The tradeoff is complexity and time upfront for long-term stability. The practical reality is that many people need both strategies. Theraflu for the cold that hits this week; Tezspire (if asthma is poorly controlled) to prevent the next three colds. They’re not competing products—they’re addressing different time horizons.
Drug Interactions and Safety Concerns in Dementia Care
Theraflu contains acetaminophen, dextromethorphan, and phenylephrine—each with potential interactions. The acetaminophen adds to any other pain medications or cold medicines the patient might take, risking liver toxicity if cumulative doses exceed guidelines. The dextromethorphan can interact with certain antidepressants or dementia medications, and it has the potential to cause sedation or confusion. The phenylephrine can raise blood pressure dangerously in someone on stimulant medications or some types of blood pressure meds, and it may worsen urinary retention—a common issue in older men. Tezspire interactions are fewer but more complex.
It’s not recommended for patients with active infections and requires careful monitoring in anyone with a history of immunosuppression or malignancy. Someone with dementia taking multiple medications for behavioral or neurological symptoms needs a geriatrician or pharmacist review before starting Tezspire, because the medication interacts with the immune system in ways that can’t be predicted individually. A critical warning: older adults with dementia are at high risk for medication errors and adverse events. Theraflu is so accessible that family members might give it without checking other medications or understanding contraindications. Tezspire’s complexity might lead to missed doses or misunderstanding of its purpose. Either way, the medication requires supervision and knowledge.
When Congestion Persists Despite Treatment
Some people take Theraflu and don’t get adequate relief—either because their congestion is severe, because they’ve developed tolerance, or because something other than a cold is causing the stuffiness. Chronic rhinosinusitis, allergies, nasal polyps, or septum deviation all cause congestion that Theraflu can’t fix.
A 68-year-old with dementia might be treated with Theraflu repeatedly for “colds” when the real problem is seasonal allergies, and no amount of phenylephrine will help until the underlying allergy is treated. For these people, Tezspire (if asthma is the underlying issue) or other interventions—nasal saline, intranasal corticosteroids, or allergy management—become necessary. The lesson is that persistent stuffiness despite appropriate treatment warrants further evaluation, not just more medication.
The Future of Congestion Management and Respiratory Health in Aging
Medical understanding of how respiratory health affects cognitive function continues to evolve. Research increasingly shows that chronic hypoxia and repeated respiratory infections accelerate cognitive decline in older adults.
This reframes the question from “which clears stuffiness faster” to “how do we prevent congestion and respiratory problems from happening repeatedly?” For older adults with dementia, the future may involve more proactive approaches like Tezspire—biologic therapies that prevent exacerbations rather than treating acute episodes. That said, Theraflu and other rapid-relief options will always be necessary for the acute cold or flu that catches everyone by surprise. The goal is integrating both strategies: preventing the predictable, chronic problems while having effective tools for unexpected acute ones.
Conclusion
Theraflu wins on speed and immediate relief—it’s the right choice for sudden cold or flu congestion and works within 30 minutes to an hour. Tezspire is a prescription biologic for chronic asthma that reduces overall inflammation and respiratory exacerbations over weeks, making it valuable for people with persistent breathing problems but not for rapid relief. The choice between them depends entirely on the situation: acute cold stuffiness calls for Theraflu; chronic asthma or recurrent respiratory problems might benefit from Tezspire alongside other management strategies.
For someone with dementia or cognitive decline, respiratory health directly matters because clear breathing supports oxygen delivery to the brain. Whether using Theraflu for acute relief or considering Tezspire for chronic asthma, any medication should be reviewed by a doctor who understands the patient’s full medical picture, including their cognitive status and other medications. The fastest relief isn’t always the safest or best choice for someone with complex medical needs.
